2022 World Conference on Lung Cancer (ePosters)-EP16.03-044. Genomic Evidence Depicting Clonal Evolution of Lung Adenosquamous Carcinoma

Pdf Summary

Adenosquamous carcinoma (ASC) is a rare type of non-small cell lung cancer that contains both adenocarcinoma (AC) and squamous cell carcinoma (SCC) components. However, the genomic background, tumor origins, and evolutionary mechanisms of ASC are not fully understood. In this study, researchers analyzed the genomic profiles and mutational signatures of ASC samples and compared them to lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) cases. They found that the AC and SCC components of ASC shared clonal origins and had both shared and unique mutations and copy number variations. They also observed a smoking-associated mutational signature in EGFR-wildtype LUSC, while EGFR-positive LUADs, ASCs, and LUSCs had similar signature profiles. The researchers also established a xenograft model from an ASC patient to show histologic transformation. Furthermore, a separate cohort of EGFR-positive LUAD, ASC, and LUSC patients was evaluated for their response to tyrosine kinase inhibitors, and it was found that ASCs could benefit from this treatment, similar to other subtypes of non-small cell lung cancer. In conclusion, this study provides genomic evidence depicting the clonal evolution of ASC and suggests that AC and SCC components of ASC may undergo phenotypic transitions into pure squamous cell carcinoma. The findings also highlight the potential effectiveness of tyrosine kinase inhibitors in treating ASC.

Asset Subtitle

Yuchen Han

Meta Tag

Speaker Yuchen Han

Topic Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapies

Keywords

Adenosquamous carcinoma

non-small cell lung cancer

adenocarcinoma

squamous cell carcinoma

genomic profiles

mutational signatures

copy number variations

smoking-associated mutational signature

xenograft model

tyrosine kinase inhibitors